3RX2
Crystal Structure of Human Aldose Reductase Complexed with Sulindac Sulfone
3RX2 の概要
エントリーDOI | 10.2210/pdb3rx2/pdb |
関連するPDBエントリー | 3RX3 3RX4 |
分子名称 | Aldose reductase, NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, 2-[(3Z)-6-fluoranyl-2-methyl-3-[(4-methylsulfonylphenyl)methylidene]inden-1-yl]ethanoic acid, ... (4 entities in total) |
機能のキーワード | aldose reductase, oxidoreductase |
由来する生物種 | Homo sapiens (human) |
細胞内の位置 | Cytoplasm: P15121 |
タンパク質・核酸の鎖数 | 1 |
化学式量合計 | 39185.51 |
構造登録者 | |
主引用文献 | Zheng, X.,Zhang, L.,Zhai, J.,Chen, Y.,Luo, H.,Hu, X. The molecular basis for inhibition of sulindac and its metabolites towards human aldose reductase Febs Lett., 586:55-59, 2012 Cited by PubMed Abstract: Sulindac (SLD) exhibits both the highest inhibitory activity towards human aldose reductase (AR) among popular non-steroidal anti-inflammatory drugs and clear beneficial clinical effects on Type 2 diabetes. However, the molecular basis for these properties is unclear. Here, we report that SLD and its pharmacologically active/inactive metabolites, SLD sulfide and SLD sulfone, are equally effective as un-competitive inhibitors of AR in vitro. Crystallographic analysis reveals that π-π stacking favored by the distinct scaffold of SLDs is pivotal to their high AR inhibitory activities. These results also suggest that SLD sulfone could be a potent lead compound for AR inhibition in vivo. PubMed: 22155003DOI: 10.1016/j.febslet.2011.11.023 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (1.9 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード